Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases
Authors:
Open Access
- 28 June 2022
- journal article
- letter
- Published by Elsevier in Journal of Clinical Virology Plus
- Vol. 2 (3) , 100097
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodiesThe Lancet Infectious Diseases, 2022
- High incidence of sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variantmedRxiv, 2022
- Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19JAMA, 2022
- Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2New England Journal of Medicine, 2022
- Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab UseNew England Journal of Medicine, 2022
- Antibody evasion properties of SARS-CoV-2 Omicron sublineagesNature, 2022
- Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2bioRxiv, 2022
- Antibody Evasion Properties of SARS-CoV-2 Omicron SublineagesbioRxiv, 2022
- Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic ReviewInternational Journal of Molecular Sciences, 2021
- The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2bioRxiv, 2021